Investigational drug · Phase 3
almonertinib
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Advanced Solid Tumors, Relapsed or Advanced Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
81
Any phase or sponsor naming "almonertinib"
First trial start
2021
Mar 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "almonertinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Advanced Solid Tumors
- Relapsed or Advanced Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "almonertinib" as an intervention, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
Fudan UniversityAcademic, hospital or other
NCT06613633 · 4,000 participants · Start Sep 1, 2018 · Primary completion Aug 1, 2024
Drug: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) · For: Third-generation TKI; NSCLC (Advanced Non-small Cell Lung Cancer)
Sites: Wuhan, China; Shanghai, China · 3 sites in all
- A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerPivotal-lookingRecruiting
Hansoh BioMedical R&D CompanyIndustry
NCT06417008 · 1,080 participants (planned) · Start May 28, 2024 · Primary completion Jun 1, 2026
Drug: HS-20117; Aumolertinib · For: Non-Squamous Non-Small Cell Lung Cancer
Sites: Tianjin, China; Hangzhou, China
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04324164 · 800 participants (planned) · Start Mar 24, 2020 · Primary completion Dec 24, 2025
Drug: Third-generation EGFR-TKI; EGFR-TKI · For: Non-small Cell Lung Cancer
Sites: Changsha, China
Fudan UniversityAcademic, hospital or other
NCT06604689 · 800 participants (planned) · Start Sep 30, 2024 · Primary completion Apr 1, 2025
Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) · For: NSCLC (Advanced Non-small Cell Lung Cancer); Brain Metastasases
Sites: Shanghai, China
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT04423185 · 770 participants (planned) · Start Aug 15, 2020 · Primary completion Jul 1, 2026
Drug: Almonertinib 110 MG; Dacomitinib 45 MG and 9 more · For: Rare Tumor
Sites: Beijing, China
- Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective StudyPivotal-lookingStatus unknown
Tian XieAcademic, hospital or other
NCT04401059 · 744 participants (planned) · Start Nov 9, 2020 · Primary completion Sep 30, 2025
Drug: Elemene plus first or third generation EGFR-TKIs; First or third generation EGFR-TKIs · For: Carcinoma; Non-Small-Cell Lung Cancer; Adenocarcinoma
Sites: Nantong, China; Panjin, China; Shanghai, China · 7 sites in all
- An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.Pivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07863167 · 660 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 30, 2028
Drug: adebrelimab + SHR-A2009; paclitaxel or pemetrexed combined with carboplatin +adebrelimab and 11 more · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China
Xin LiAcademic, hospital or other
NCT07838532 · 637 participants · Start Mar 24, 2020 · Primary completion Dec 31, 2024
Drug: Aumolertinib monotherapy (development code: HS-10296) · For: Non Small Cell Lung Cancer; T790M; EGFR Activating Mutation
Sites: Nanjing, China
- Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsPivotal-lookingActive, not recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT04923906 · 624 participants (planned) · Start Aug 11, 2021 · Primary completion Jun 18, 2024
Drug: Aumolertinib; Placebo Aumolertinib · For: Non-small Cell Lung Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Successful rechallenge with almonertinib and corticosteroids after gefitinib-induced interstitial lung disease: A case report and literature review.
Liu J, Wei T, Bao Z, et al. · Medicine (Baltimore) 2026
- Simultaneous determination of osimertinib and almonertinib concentrations in human plasma and cerebrospinal fluid using UPLC-MS/MS method and its clinical applications.
Yin J, Zuo Y, Wang X, et al. · Front Pharmacol 2026
- Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis.
Rong B, Pan H, Fu T, et al. · Front Pharmacol 2026
- Case Report: An enlarging left ventricular mass during anticoagulation in a patient receiving almonertinib after thoracic radiotherapy: diagnostic uncertainty and individualized management.
He B, Tan Y, Kong F, et al. · Front Cardiovasc Med 2026
- Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study.
Cao T, Chen L, Li Y, et al. · Front Med (Lausanne) 2026
- Anlotinib combined with almonertinib reverses almonertinib resistance in lung adenocarcinoma by inhibiting the c-MET/PI3K/AKT pathway.
Lu D, Peng B, Ouyang W · World J Surg Oncol 2026
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.